For hospital care, three broad classifications of studies were identified: on treatment of acute coronary syndromes, on antibiotic prophylaxis for surgical patients, and on thromboembolic prophylaxis for surgical patients (see Table 3-11). Seven studies addressed acute myocardial infarction. Within the first 24 hours of hospitalization for a myocardial infarction, 85–93 percent had received aspirin (Sanborn et al., 2004; Granger et al., 2005; Roe et al., 2005), and 66–78 percent beta-blockers (Sanborn et al., 2004; Granger et al., 2005; Roe et al., 2005). Among patients discharged with a diagnosis of acute myocardial infarction, aspirin was prescribed for 53–93 percent of ideal candidates (those with no known contraindication), beta-blockers for 53–83 percent of ideal candidates, and angiotensin converting enzyme (ACE) inhibitors for 59–83 percent of ideal candidates (Alexander et al., 1998; Petersen et al., 2001, 2003; Krumholz et al., 2003; Sanborn et al., 2004; Granger et al., 2005; Roe et al., 2005). Rates of prophylaxis for bacterial infections among surgical patients ranged from 70 to 98 percent (Heineck et al., 1999; Vaisbrud et al., 1999; Gupta et al., 2003; van Kasteren et al., 2003; Bedouch et al., 2004; Quenon et al., 2004). Rates of thromboembolic prophylaxis varied greatly—from 5 to 81 percent (Ageno et al., 2002; Ahmad et al., 2002; Aujesky et al., 2002; Campbell et